The pharmaceutical company Linux Laboratories, based in Chennai, has raised $70 million in equity capital from the ChrysCapital and Tata Capital Healthcare Fund III funds.
This deal represents a combination of primary capital raising and secondary purchase. As a result, ChrysCapital will receive a significant minority stake in Linux, while Tata Capital Healthcare Fund II (TCHF II) will fully exit the company, realizing a return of approximately 4 times.
Linux stated that it plans to use the raised funds to support the next stage of its growth. This includes deepening its presence in core specialized areas, entering adjacent therapeutic fields, continuing brand acquisitions, and further investing in manufacturing capabilities and research and development.
Founded in 2007, Linux is a domestic platform focused on niche specializations, possessing a portfolio of over 125 brands covering more than 400 product lines. Its main specialization is central nervous system (CNS) therapies, including treatment for epilepsy, neuropathic pain, depression, and autism, while the company has expanded its operations into dermatology, cardio-diabetes, and nutraceuticals.
Co-founder and CEO of Linux Laboratories, S Ananda Kumar, noted that the company was established on the belief that a focused, science-backed portfolio ensuring healthcare accessibility and quality can compete with the largest players in the Indian pharmaceutical market.
According to the statement, Linux combined organic and inorganic growth by integrating and scaling the portfolios of Biomedica and Indiabulls Pharmaceuticals, as well as brands acquired from Cipla and Dr. Reddy’s Laboratories. The company also operates its own WHO-GMP certified manufacturing facility, which supports backward integration for branded business while strengthening its Contract Development and Manufacturing Organization (CDMO) operations and its export presence in various countries.
Kshitij Seth, Managing Director of ChrysCapital Advisors, emphasized that this investment aligns with ChrysCapital's strategy to support fast-growing domestic companies dealing with chronic diseases and led by dynamic entrepreneurs.
Linux Laboratories noted that the Indian branded drug market continues to attract strong investment interest. This interest is driven by the growing burden of chronic and subchronic conditions, as well as the increasing share of specialist-focused and niche portfolios.
Avendus Capital served as the exclusive financial advisor for Linux in this transaction.